Serinus Biosciences Analysis: $500K Raised
What is Serinus Biosciences?
Serinus Biosciences develops precision medicine drugs targeting drug-resistant cancer by using AI to identify vulnerabilities in resistant tumors.
Employees
6
Founded
2022
Revenue
$0-1M
Company Stage
Seed
YC Batch
S22
Product Features & Capabilities
- ResCuETM AI platform for identifying druggable vulnerabilities, cost-effective mapping of market opportunities, clinically assayable resistance biomarkers, druggable targets with progressable chemical matter.
How much Serinus Biosciences raised
Pre-Seed - $500,000
September 7, 2022Lead Investor: Y Combinator
Who are the founders of Serinus Biosciences
AY
Adam Yaari
Founder/CEO
MS
Maxwell Sherman
Founder/CTO
Investors
- Y Combinator
- Illumina Ventures
- Sapir Venture Partners
- Endless Frontier Labs
- Merck Digital
- Phoenix Investment Club
